Eli Lilly aims to cut 200 R&D jobs
The Indianapolis-based drugmaker has offered many of its research and development employees a compensation package if they leave the company.
The Indianapolis-based drugmaker has offered many of its research and development employees a compensation package if they leave the company.
Eli Lilly and Co. CEO Dave Ricks said he was encouraged by President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. health-care system.
For drugmakers, including Indianapolis-based Eli Lilly and Co., a meeting Tuesday with President Donald Trump was a dose of happy pills.
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.
The Indianapolis-based drugmaker got a revenue boost from a host of new medications but also saw sales fall sharply for some older products.
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
Alex Azar, president of Lilly USA LLC since 2012, is leaving the company just as his unit is about to lose a huge swath of sales personnel. The drugmaker announced a series of changes Thursday under new CEO David Ricks.
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
Eli Lilly and Co. shares rose sharply Thursday morning after the company presented a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key Alzheimer’s treatment in testing.
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
President-elect Donald Trump promised to drive down the cost of medicines, defying investors who saw a boon in his election last month and injecting himself again into a contentious economic debate.
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
Analysts are all over the map on how investors should react to the Indianapolis-based drugmaker’s news that a promising drug failed to help patients.
Investors pummeled Eli Lilly and Co.’s stock Wednesday on the news that its experimental drug for Alzheimer’s disease failed to help patients, but a chorus of pharmaceutical analysts say they weren’t shocked by the setback.
John Lechleiter told local leaders Friday morning that while community engagement might not immediately impact the bottom line, it can be beneficial to a company’s ongoing mission.